Marinomed Biotech AG | WebDisclosure

Basculer en Français

10368	Companies
215967	Keywords
145708	Articles
114374	Press releases

Home
Companies
Marinomed Biotech AG

PRESS RELEASE

published on 10/01/2025 at 12:18, 7 months 6 days ago

Original-Research: Marinomed Biotech AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research reaffirmed a Buy rating and EUR 50.00 price target for Marinomed Biotech AG. H1 results were in line with expectations, with nearly tripled sales and positive AEBITDA amid strategic financial moves

First Berlin Equity Research BUY Rating Marinomed Biotech AG H1 Results EUR 50.00 Price Target
BRIEF

published on 09/17/2025 at 13:53, 7 months 20 days ago

Marinomed Biotech AG annonce une croissance significative au premier semestre 2025

Résultats Financiers Augmentation Des Revenus Croissance Du Résultat D'exploitation (EBIT) Croissance De La Biotechnologie Mesures De Capital
BRIEF

published on 09/17/2025 at 13:53, 7 months 20 days ago

Marinomed Biotech AG Reports Significant Growth in H1 2025

Financial Results Revenue Increase EBIT Growth Capital Measures Biotech Growth
PRESS RELEASE

published on 09/17/2025 at 13:48, 7 months 20 days ago

Marinomed Biotech AG announces results for the first half year of 2025
Marinomed Biotech AG reports strong financial results for the first half of 2025, with revenues of EUR 7.2 million and EBIT of EUR 21.0 million. The company secured financing through capital measures

Revenues Financial Results EBIT Marinomed Biotech AG Capital Measures
BRIEF

published on 09/16/2025 at 15:27, 7 months 21 days ago

Marinomed Biotech AG annonce une augmentation de capital

Investissement Augmentation De Capital Marinomed Biotech AG Émission D'actions Industrie Biotechnologique
BRIEF

published on 09/16/2025 at 15:27, 7 months 21 days ago

Marinomed Biotech AG Announces Capital Increase

Investment Biotech Industry Capital Increase Share Issuance Marinomed Biotech AG
PRESS RELEASE

published on 09/16/2025 at 15:22, 7 months 21 days ago

EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 61.607 no-par value bearer shares at an issue price of EUR 17,50 per share
Marinomed Biotech AG resolves capital increase by issuing 61.607 bearer shares at EUR 17,50 per share, excluding statutory subscription rights

Capital Increase Marinomed Biotech AG Subscription Rights Bearer Shares EUR 17,50
BRIEF

published on 09/01/2025 at 12:01, 8 months 6 days ago

Marinomed Biotech AG obtient un accord d'émission d'obligations convertibles de 2,5 millions d'euros

Financement Stratégie D'investissement Droits Des Actionnaires Marinomed Biotech Obligation Convertible
BRIEF

published on 09/01/2025 at 12:01, 8 months 6 days ago

Marinomed Biotech AG Secures EUR 2.5 Million Convertible Bond Agreement

Financing Investment Strategy Shareholder Rights Convertible Bond Marinomed Biotech
PRESS RELEASE

published on 09/01/2025 at 11:56, 8 months 6 days ago

EQS-Adhoc: Marinomed Biotech AG: Agreement on the key terms of the issue of a secured EUR 2.5mn convertible bond
Marinomed Biotech AG announces agreement on key terms for a secured EUR 2.5mn convertible bond issue, including interest rate and conversion price

Marinomed Biotech AG Convertible Bond Secured EUR 2.5mn Key Terms

Accesswire

Published on 05/08/2026 at 00:45, 49 minutes ago

Route1 Announces First Quarter 2026 Financial Results Notification
Published on 05/08/2026 at 00:00, 1 hour 34 minutes ago

Redwood AI Approved to Receive National Research Council of Canada Funding for its Q-SAFE Chemical Screening Project for Defence and Security Applications
Published on 05/07/2026 at 23:30, 2 hours 4 minutes ago

Faraday Copper Reports First Quarter 2026 Financial Results
Published on 05/07/2026 at 23:15, 2 hours 19 minutes ago

BULGOLD Adopts Semi-Annual Financial Reporting
Published on 05/07/2026 at 22:05, 3 hours 29 minutes ago

MicroVision and Avular Collaborate to Advance Autonomous Sensing and Drone Integration for Next-Generation Infrastructure Applications

View all ACCESSWIRE

EQS Group

Published on 05/07/2026 at 23:23, 2 hours 10 minutes ago

H1 25/26: Challenging environment and significant changes in IT market // Revised forecast // Programme to boost competitiveness
Published on 05/07/2026 at 23:14, 2 hours 19 minutes ago

EQS-Adhoc: All for One Group SE revises forecast for 2025/26 financial year // »Precision« programme to boost competitiveness approved
Published on 05/07/2026 at 22:05, 3 hours 29 minutes ago

Univar Solutions Announces Leadership Evolution
Published on 05/07/2026 at 20:42, 4 hours 51 minutes ago

RHÖN-KLINIKUM AG reports stable development in the first quarter of 2026
Published on 05/07/2026 at 18:46, 6 hours 48 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 05/07/2026 at 19:15, 6 hours 19 minutes ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 6 hours 19 minutes ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 6 hours 28 minutes ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 6 hours 28 minutes ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 6 hours 34 minutes ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE